ATE340563T1 - DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT - Google Patents

DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT

Info

Publication number
ATE340563T1
ATE340563T1 AT01906794T AT01906794T ATE340563T1 AT E340563 T1 ATE340563 T1 AT E340563T1 AT 01906794 T AT01906794 T AT 01906794T AT 01906794 T AT01906794 T AT 01906794T AT E340563 T1 ATE340563 T1 AT E340563T1
Authority
AT
Austria
Prior art keywords
shell
dosage form
release
active ingredients
zero order
Prior art date
Application number
AT01906794T
Other languages
English (en)
Inventor
Bret Berner
Jenny Louie-Helm
Gloria Gusler
John N Shell
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23983134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340563(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Depomed Inc filed Critical Depomed Inc
Application granted granted Critical
Publication of ATE340563T1 publication Critical patent/ATE340563T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01906794T 2000-02-04 2001-01-30 DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT ATE340563T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49894500A 2000-02-04 2000-02-04

Publications (1)

Publication Number Publication Date
ATE340563T1 true ATE340563T1 (de) 2006-10-15

Family

ID=23983134

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906794T ATE340563T1 (de) 2000-02-04 2001-01-30 DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT

Country Status (12)

Country Link
US (6) US7736667B2 (de)
EP (1) EP1251832B1 (de)
JP (1) JP2003521507A (de)
AT (1) ATE340563T1 (de)
AU (1) AU767812B2 (de)
CA (1) CA2396782A1 (de)
DE (1) DE60123384T2 (de)
ES (1) ES2270982T3 (de)
IL (2) IL150568A0 (de)
MX (1) MXPA02007254A (de)
PT (1) PT1251832E (de)
WO (1) WO2001056544A2 (de)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
WO2002055009A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1438027A1 (de) 2001-10-25 2004-07-21 DepoMed, Inc. Behandlungsmethode unter verwendung einer losartan enthaltenden darreichungsform mit verlängerter magenverweilzeit
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
EP1476139B1 (de) * 2002-02-21 2017-05-17 Valeant Pharmaceuticals Luxembourg S.à.r.l. Dosierformen mit kontrollierter freisetzung
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
JP2006516976A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 機能性腸障害を処置する方法
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CN100459982C (zh) * 2004-08-30 2009-02-11 鲁南制药集团股份有限公司 去氧氟尿苷的分散片剂型
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
PL1919466T3 (pl) 2005-07-11 2012-05-31 Cortria Corp Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
US8728521B2 (en) * 2005-12-27 2014-05-20 Hemant N. Joshi Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
US20070148227A1 (en) * 2005-12-27 2007-06-28 Hemant Joshi Physically/molecularly distributed and/or chemically bound medicaments in capsule shells
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
MX2009013494A (es) * 2007-06-11 2010-01-18 Procter & Gamble Agente benefico que contiene particulas de suministro.
WO2009017716A2 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
US8329750B2 (en) * 2008-02-11 2012-12-11 Depomed, Inc. Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2774226T3 (es) 2008-05-15 2020-07-17 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
WO2010019915A1 (en) 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
US9744142B2 (en) 2009-05-05 2017-08-29 Board Of Regents, The University Of Texas Systems Formulations of volatile anesthetics and methods of use for reducing inflammation
NZ598922A (en) * 2009-08-31 2014-03-28 Depomed Inc Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US20110052700A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US20110135728A1 (en) * 2009-12-08 2011-06-09 Miller Jennifer L Gastric retentive pharmaceutical compositions for extended release of polypeptides
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2389934A1 (de) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Tablettenformulierungen mit Pregabalin mit gesteuerter Freisetzung
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
EP2648754A4 (de) 2010-12-07 2016-02-24 Philadelphia Health & Educatio Verfahren zur hemmung von krebs-metastasen
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US20140018404A1 (en) 2010-12-16 2014-01-16 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
ES2544735T3 (es) * 2011-03-25 2015-09-03 Purdue Pharma L.P. Formas de dosificación farmacéutica de liberación controlada
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
DE102011051653A1 (de) 2011-07-07 2013-01-10 Lts Lohmann Therapie-Systeme Ag Quellfähige Manteltablette
BR112014010417A2 (pt) 2011-11-01 2014-11-18 Celgene Corp Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US20140343452A1 (en) * 2011-12-21 2014-11-20 Eatlittle Inc. Pseudobezoar-Based Intraluminal Gastrointestinal Cleansing and Biospy
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
US9388126B2 (en) 2012-07-19 2016-07-12 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
ES2689906T3 (es) 2012-08-09 2018-11-16 Dynamis Therapeutics, Inc. Meglumina para reducir los niveles altos de triglicéridos
DK2941233T3 (da) 2013-01-07 2020-10-19 Univ Pennsylvania Sammensætninger og fremgangsmåder til behandling af kutant T-celle-lymfom
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3878445A3 (de) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit
BR112015032961B1 (pt) 2013-07-02 2021-11-30 Ecoplanet Environmental Llc Formulação, e, métodos para tratar resíduos humanos ou animais e para eliminar ou reduzir crescimento microbiano em um local de tratamento
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US9908915B2 (en) 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
WO2015157262A1 (en) 2014-04-07 2015-10-15 Women & Infants Hospital Of Rhode Island Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10485758B2 (en) 2014-06-02 2019-11-26 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US10799541B2 (en) * 2014-07-01 2020-10-13 Probi USA, Inc. Bi-layer dual release probiotic tablets
WO2016028753A1 (en) 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
SMT202300081T1 (it) 2014-08-22 2023-05-12 Celgene Corp Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi
US10940109B2 (en) 2014-08-27 2021-03-09 The Regents Of The University Of Colorado Multilayer polymeric matrix based medical devices
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
BR112017017729A2 (pt) 2015-02-20 2018-04-10 Osmotica Kereskedelmi Es Szolgaltato Kft forma de dosagem oral de liberação controlada de agonista de receptor gaba
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
PL3298140T3 (pl) 2015-05-19 2024-11-12 Yale University Kompozycje do leczenia patologicznych stanów zwapnienia i sposoby ich stosowania
WO2016201288A1 (en) 2015-06-12 2016-12-15 Brown University Novel antibacterial compounds and methods of making and using same
RU2697836C2 (ru) 2015-06-26 2019-08-21 Кореа Юнайтед Фарм. Инк. Комбинированный препарат мозаприда и рабепразола
EP3316890B1 (de) 2015-06-30 2023-09-06 Neurad Ltd. Neuartige verbindung zur modulierung der beatmungssteuerung und verfahren zur herstellung und verwendung davon
CN108347922B (zh) * 2015-08-18 2021-03-16 巴斯夫欧洲公司 具有聚乙烯醇和聚噁唑啉的壳的农业化学微胶囊
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
IL311873A (en) 2015-10-15 2024-06-01 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
WO2017075145A1 (en) 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
JP2018537093A (ja) 2015-11-20 2018-12-20 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
CA3007363A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
US10137130B2 (en) 2016-02-26 2018-11-27 Celgene Corporation Methods of treatment of malignancies
EP3448369B1 (de) 2016-04-29 2025-06-25 The Regents of The University of Colorado, A Body Corporate Hemmung oder abbau von hdac11 zur behandlung von fettleibigkeit, hyperlipidämie, typ-ii-diabetes, metabolischem syndrom oder insulinresistenz, und zur förderung der gewichtsabnahme und/oder zur linderung oder verhinderung einer gewichtszunahme
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
WO2018026894A1 (en) 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
JP2019532915A (ja) 2016-08-05 2019-11-14 イエール ユニバーシティ 小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法
WO2018045229A1 (en) 2016-09-01 2018-03-08 Mebias Discovery Llc Substituted ureas and methods of making and using same
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
WO2018102799A1 (en) 2016-12-02 2018-06-07 Clexio Biosciences Ltd. Gastric residence system
EP3571196B1 (de) 2017-01-19 2023-01-04 Temple University Of The Commonwealth System Of Higher Education Neuartige verbrückte bicycloalkyl-substituierte aminothizole und verfahren zu deren verwendung
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
EP3618828B1 (de) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Verfahren zur behandlung von myeloproliferativem neoplasma
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
WO2018232413A1 (en) 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CA3071345A1 (en) 2017-07-28 2019-01-31 Yale University Anticancer drugs and methods of making and using same
SG11202002060XA (en) 2017-09-08 2020-04-29 Univ Colorado Regents Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
JP7293209B2 (ja) * 2017-10-20 2023-06-19 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形
US20200323895A1 (en) 2017-11-27 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
EP3720537B1 (de) 2017-12-04 2025-03-19 Clexio Biosciences Ltd. Langwirkendes magenverweilsystem
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
AU2019212241A1 (en) 2018-01-24 2020-08-13 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
EP3802572A4 (de) 2018-05-25 2022-03-23 Temple University - Of The Commonwealth System of Higher Education Entfernung von bakteriellen biofilmen mittels anti-amyloider monoklonaler antikörper
KR20210015892A (ko) 2018-05-29 2021-02-10 세르시 테라퓨틱스 인코포레이티드 통증 치료를 위한 화합물, 이를 포함하는 조성물 및 이를 사용하는 방법
ES2861153T3 (es) 2018-06-18 2021-10-05 Composiciones de liberación prolongada que comprenden piridostigmina
TWI869058B (zh) 2018-07-27 2025-01-01 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
AU2019321654B8 (en) 2018-08-17 2025-08-07 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
US12458601B2 (en) 2018-10-19 2025-11-04 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
CN113365636A (zh) 2019-01-30 2021-09-07 萨尼菲特治疗有限公司 用于增加组织灌注的磷酸肌醇化合物
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US10918700B2 (en) 2019-04-12 2021-02-16 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
IL287617B2 (en) 2019-05-09 2024-11-01 Feinstein Institutes For Medical Research Hmgb1 antagonist
CA3143196A1 (en) 2019-06-12 2020-12-17 The Wistar Institute Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (de) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
EP4162036A1 (de) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Lösliche enpp1- oder enpp3-proteine und verwendungen davon
CN112034057B (zh) * 2020-08-16 2022-04-01 江苏正大清江制药有限公司 一种测定头孢呋辛酯原料中高分子聚合物的方法
EP4216949A4 (de) 2020-09-28 2024-12-11 Yale University Selektive agonisten des 5-ht2a-rezeptors und verfahren zur verwendung
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
EP4036097A1 (de) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6-substituierte derivatverbindungen
IL318658A (en) 2022-07-29 2025-03-01 Sanifit Therapeutics S A IP4-4,6-Substituted Derivative Compounds for Use in the Treatment, Inhibition of Progression, and Prevention of Ectopic Calcification
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
IL319372A (en) 2022-09-06 2025-05-01 Hadasit Med Res Service Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
WO2025037248A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
ZA722664B (en) 1971-05-18 1973-01-31 Smith Kline French Lab Lyered bolus for animal husbandry providing for immediate and sustained release of medicament
CH582002A5 (de) * 1972-06-09 1976-11-30 Purdue Research Foundation
US4088798A (en) 1975-11-11 1978-05-09 Sandoz, Inc. Methods for the preparation of controlled gastric residence time medicament formulations
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
US4629620A (en) 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4789549A (en) 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
US5876752A (en) 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5391378A (en) 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
US5827538A (en) 1993-07-22 1998-10-27 Pfizer Inc. Osmotic devices having vapor-permeable coatings
US5415688A (en) 1993-09-20 1995-05-16 Ameron, Inc. Water-borne polysiloxane/polysilicate binder
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
KR100364328B1 (ko) * 1996-08-29 2002-12-26 사노피-신델라보 알푸조신 염산염의 제어방출 정제
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
DK0961611T3 (da) * 1997-01-14 2002-07-15 Lohmann Therapie Syst Lts Ekspanderbart gastroretentivt terapeutisk system med kontrolleret frisætning af aktivt stof i den gastrointestinale kanal
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
WO1999007342A1 (en) * 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
CA2220038A1 (en) * 1998-01-05 1999-07-05 Amina Odidi Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data

Also Published As

Publication number Publication date
MXPA02007254A (es) 2002-12-09
AU767812B2 (en) 2003-11-27
WO2001056544A2 (en) 2001-08-09
EP1251832B1 (de) 2006-09-27
AU3466101A (en) 2001-08-14
US20130164377A1 (en) 2013-06-27
EP1251832A2 (de) 2002-10-30
US20110236485A1 (en) 2011-09-29
US8329215B2 (en) 2012-12-11
US20150182541A1 (en) 2015-07-02
WO2001056544A3 (en) 2002-05-02
US20030104062A1 (en) 2003-06-05
IL150568A (en) 2007-12-03
DE60123384D1 (de) 2006-11-09
IL150568A0 (en) 2003-02-12
US8945619B2 (en) 2015-02-03
US7736667B2 (en) 2010-06-15
DE60123384T2 (de) 2007-08-02
HK1050493A1 (en) 2003-06-27
US9597338B2 (en) 2017-03-21
CA2396782A1 (en) 2001-08-09
PT1251832E (pt) 2007-01-31
US20100272808A1 (en) 2010-10-28
US8043630B2 (en) 2011-10-25
US20170172930A1 (en) 2017-06-22
ES2270982T3 (es) 2007-04-16
JP2003521507A (ja) 2003-07-15

Similar Documents

Publication Publication Date Title
ATE340563T1 (de) DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
NO20014859D0 (no) Raskt dispergerbare doseringsformer inneholdende fiskegelatin
IL153464A0 (en) A controlled release oral drug dosage form
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DE59802670D1 (de) Osmotisches arzneimittelfreisetzungssystem
BR0307473A (pt) Forma de dosagem farmacêutica para distribuição por via mucosa
CO4940409A1 (es) Tableta cubierta con pelicula para seguridad mejorada del tracto gastrointestinal superior
TR200002207T1 (tr) Slekoksib bileşikleri.
EP1365749A4 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AP2003002763A0 (en) Controlled release formulations for oral administration
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
DK1292303T3 (da) Stabil farmaceutisk formulering omfattende torsemidmodifikation II
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
WO2003037296A3 (en) Methods and dosage forms for improving the bioavailability of therapeutic agents
RU2003133155A (ru) Способ эрадикации инфекции helicobacter pylori в желудке
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
MY145885A (en) Controlled release formulations for oral administration

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties